| 货号 | AF3020-SP |
| 别名 | SUMO2/3/4 | 全称 | Small Ubiquitin-like Modifier 2, 3, & 4 |
| 反应种属 | Human/Mouse |
| 应用 | Western Blot(1 µg/mL) |
| 目标/特异性 | Detects endogenous human and mouse proteins modified with SUMO2, 3, or 4 in Western blots. Because of the high level of sequence homology, this antibody has equivalent reactivity to SUMO2, SUMO3, and SUMO4 based in Western blots with recombinant SUMO protein. Cross-reactivity to recombinant human SUMO1 was minimal in Western blots. |
| 使用方法 | Western Blot: 1 µg/mL |
| 来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | E. coli-derived recombinant human SUMO2 Ala2-Tyr95 Accession # P61956 |
| 生物活性 | Human, Mouse |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Small Ubiquitin-like Modifiers (SUMOs) are a family of small, related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed sumoylation. Unlike ubiquitination, which targets proteins for degradation, sumoylation participates in a number of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. All SUMO proteins share the conserved ubiquitin domain and the C-terminal diglycine cleavage/attachment site. Human SUMO2, also known as Sentrin2 and SMT3B is synthesized as a 95 amino acid (aa), 11 kDa propeptide that contains a two aa C-terminal prosegment, and an 18 aa N-terminal protein interacting region (aa 33‑50). Following prosegment cleavage, the C-terminal glycine is enzymatically attached to a lysine on a target protein. Human SUMO2 shares 100% sequence identity to SUMO-2 from mouse. SUMO2 also has very high sequence homology to SUMO3 and SUMO4, 86 % and 85%, respectively. SUMO2 shares only 44% sequence identity to SUMO1. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
Detection of Human SUMO2/3/4 by Western Blot. Western blot shows lysates of K562 human chronic myelogenous leukemia cell line and DU145 human prostate carcinoma cell line. PVDF membrane was probed with 1 µg/mL of Human/Mouse SUMO2/3/4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3020) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for SUMO2/3/4 at approximately 12 kDa (as indicated) along with multiple sumoylated proteins. This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 4. |
